Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,063 | 213 | 92.5% |
| Education | $408.19 | 6 | 7.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $601.69 | 30 | $0 (2023) |
| Astellas Pharma US Inc | $514.75 | 10 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $461.43 | 26 | $0 (2024) |
| PFIZER INC. | $326.65 | 18 | $0 (2024) |
| Janssen Biotech, Inc. | $284.75 | 11 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $270.15 | 3 | $0 (2017) |
| Merck Sharp & Dohme LLC | $263.12 | 8 | $0 (2022) |
| GENZYME CORPORATION | $256.37 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $241.98 | 6 | $0 (2019) |
| Abbott Laboratories | $186.70 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $650.88 | 24 | GENZYME CORPORATION ($215.90) |
| 2023 | $561.60 | 21 | Janssen Biotech, Inc. ($186.34) |
| 2022 | $666.19 | 23 | Astellas Pharma US Inc ($230.36) |
| 2021 | $216.53 | 4 | Abbott Laboratories ($186.70) |
| 2020 | $56.34 | 3 | Rigel Pharmaceuticals, Inc. ($19.79) |
| 2019 | $1,163 | 47 | Astellas Pharma US Inc ($218.26) |
| 2018 | $1,095 | 59 | Novartis Pharmaceuticals Corporation ($145.33) |
| 2017 | $1,061 | 38 | Boehringer Ingelheim Pharmaceuticals, Inc. ($270.15) |
All Payment Transactions
219 individual payment records from CMS Open Payments — Page 3 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/27/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 10/18/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $28.47 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.32 | General |
| Category: Hematology | ||||||
| 09/22/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2022 | PFIZER INC. | INLYTA (Drug), BAVENCIO, LORBRENA | Food and Beverage | In-kind items and services | $27.75 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $26.33 | General |
| Category: Oncology | ||||||
| 09/13/2022 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: Oncology | ||||||
| 09/07/2022 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: Oncology | ||||||
| 08/30/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: ONCOLOGY | ||||||
| 08/25/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: ONCOLOGY | ||||||
| 08/17/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/11/2022 | Taiho Oncology, Inc. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $25.49 | General |
| Category: Oncology | ||||||
| 08/09/2022 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Oncology | ||||||
| 08/09/2022 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: Oncology | ||||||
| 08/04/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: ONCOLOGY | ||||||
| 07/28/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: Sickle Cell Disease | ||||||
| 07/19/2022 | GENZYME CORPORATION | ENJAYMO (Biological), CABLIVI | Food and Beverage | In-kind items and services | $27.03 | General |
| Category: Hematology | ||||||
| 07/07/2022 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2021 | Abbott Laboratories | FreeStyle Libre 2 (Device) | Food and Beverage | In-kind items and services | $155.12 | General |
| Category: Diabetes Care | ||||||
| 12/13/2021 | Abbott Laboratories | FreeStyle Libre 2 (Device) | Food and Beverage | In-kind items and services | $31.58 | General |
| Category: Diabetes Care | ||||||
| 06/08/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.07 | General |
| Category: Oncology | ||||||
| 06/01/2021 | PFIZER INC. | IBRANCE (Drug), TALZENNA | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2020 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Hematology | ||||||
| 03/03/2020 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Anemia | ||||||
| 02/19/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.26 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 117 | 220 | $56,884 | $17,144 |
| 2022 | 1 | 11 | 15 | $3,000 | $954.60 |
| 2020 | 5 | 139 | 240 | $79,422 | $19,661 |
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 41 | 54 | $20,708 | $6,349 | 30.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 62 | $14,301 | $4,480 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 22 | 45 | $12,785 | $3,779 | 29.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 28 | 40 | $7,741 | $2,116 | 27.3% |
| 85060 | Blood smear interpretation by physician with written report | Facility | 2023 | 11 | 19 | $1,349 | $421.23 | 31.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 11 | 15 | $3,000 | $954.60 | 31.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 71 | 145 | $46,255 | $9,853 | 21.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 19 | 19 | $11,210 | $3,613 | 32.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 14 | 30 | $9,060 | $2,918 | 32.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 22 | 27 | $11,529 | $2,835 | 24.6% |
| 85060 | Blood smear interpretation by physician with written report | Facility | 2020 | 13 | 19 | $1,368 | $442.81 | 32.4% |
About Dr. Philip Rubin, MD
Dr. Philip Rubin, MD is a Hematology & Oncology healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336253053.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Philip Rubin, MD has received a total of $5,471 in payments from pharmaceutical and medical device companies, with $650.88 received in 2024. These payments were reported across 219 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($5,063).
As a Medicare-enrolled provider, Rubin has provided services to 267 Medicare beneficiaries, totaling 475 services with total Medicare billing of $37,760. Data is available for 3 years (2020–2023), covering 11 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Brooklyn, NY
- Active Since 08/18/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1336253053
Products in Payments
- OPDIVO (Biological) $413.01
- KISQALI (Drug) $223.48
- IMBRUVICA (Drug) $208.21
- FreeStyle Libre 2 (Device) $186.70
- IBRANCE (Drug) $155.73
- LYNPARZA (Drug) $148.52
- SARCLISA (Biological) $133.58
- Cabometyx (Drug) $126.34
- PRADAXA (Drug) $125.00
- JANUMET (Drug) $124.99
- JARDIANCE (Drug) $124.81
- Stivarga (Drug) $123.27
- DARZALEX (Biological) $119.81
- KEYTRUDA (Biological) $118.78
- VERZENIO (Drug) $117.91
- ADCETRIS (Biological) $117.25
- XTANDI (Drug) $110.22
- ZEJULA (Drug) $105.84
- PROMACTA (Drug) $101.55
- FASLODEX (Drug) $93.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Brooklyn
Perry Cook, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Yiwu Huang, Md, MD
Hematology & Oncology — Payments: $268,275
Dr. Ilya Blokh, M.d, M.D
Hematology & Oncology — Payments: $191,276
Songchuan Guo, M.d, M.D
Hematology & Oncology — Payments: $106,907
Yiqing Xu, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $51,145
Dr. Azriel Hirschfeld, M.d, M.D
Hematology & Oncology — Payments: $48,699